ATE532860T1 - B7-ähnliche moleküle und deren anwendungen - Google Patents

B7-ähnliche moleküle und deren anwendungen

Info

Publication number: ATE532860T1
Authority: AT; Austria
Prior art keywords: polypeptides; methods; provides; molecules; applications
Prior art date: 2000-09-20

Application number

AT01971167T

Other languages

English (en)

Inventor

Gary Michael Fox

John Sullivan

Paige Holst

Steven Yoshinaga

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-20

Filing date

2001-09-19

Publication date

2011-11-15

2001-09-19 Application filed by Amgen Inc filed Critical Amgen Inc

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE532860T1 publication Critical patent/ATE532860T1/de

Links

229920001184 polypeptide Polymers 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
239000011230 binding agent Substances 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)

AT01971167T 2000-09-20 2001-09-19 B7-ähnliche moleküle und deren anwendungen ATE532860T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23386700P	2000-09-20	2000-09-20
PCT/US2001/029183 WO2002024891A2 (en)	2000-09-20	2001-09-19	B7-like molecules and uses thereof

Publications (1)

Publication Number	Publication Date
ATE532860T1 true ATE532860T1 (de)	2011-11-15

Family

ID=22878998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01971167T ATE532860T1 (de)	2000-09-20	2001-09-19	B7-ähnliche moleküle und deren anwendungen

Country Status (9)

Country	Link
US (3)	US20020107363A1 (de)
EP (1)	EP1328624B1 (de)
JP (2)	JP4584536B2 (de)
AT (1)	ATE532860T1 (de)
AU (1)	AU2001291087A1 (de)
CA (1)	CA2422215A1 (de)
ES (1)	ES2372522T3 (de)
MX (1)	MXPA03002413A (de)
WO (1)	WO2002024891A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1234031T3 (en) *	1999-11-30	2017-07-03	Mayo Foundation	B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
US6965018B2 (en) *	2000-06-06	2005-11-15	Bristol-Myers Squibb Company	Antibodies directed to B7-related polypeptide, BSL-2
ATE532860T1 (de) *	2000-09-20	2011-11-15	Amgen Inc	B7-ähnliche moleküle und deren anwendungen
US7794710B2 (en) *	2001-04-20	2010-09-14	Mayo Foundation For Medical Education And Research	Methods of enhancing T cell responsiveness
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
US7244822B2 (en) *	2002-12-23	2007-07-17	Immunex Corporation	BTL-II proteins
DK1810026T3 (en)	2004-10-06	2018-07-16	Mayo Found Medical Education & Res	B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
CA2611861C (en)	2005-06-08	2017-11-28	The Brigham And Women's Hospital, Inc.	Methods and compositions for the treatment of persistent infections
WO2007082144A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and survivin in cancer
WO2007082154A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
WO2007124283A2 (en) *	2006-04-13	2007-11-01	Zymogenetics, Inc.	Tetramerizing polypeptides and methods of use
US20100075377A1 (en) *	2006-04-13	2010-03-25	West James W	Tetramerizing polypeptides and methods of use
WO2007121364A2 (en) *	2006-04-13	2007-10-25	Zymogenetics, Inc.	Tetramerizing polypeptides and methods of use
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
US20100035973A1 (en) *	2006-07-17	2010-02-11	Nationwide Children's Hospital, Inc.	Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines
KR101523391B1 (ko)	2006-12-27	2015-05-27	에모리 유니버시티	감염 및 종양 치료를 위한 조성물 및 방법
FI119513B (fi) *	2007-03-07	2008-12-15	Dextech Medical Ab	Muokatut hydroksipolymeerikonjugaatit, joilla on tappava vaikutus tuumorisoluihin
CN101784564B (zh) *	2007-07-13	2014-07-02	约翰霍普金斯大学	B7-dc变体
WO2009097017A2 (en) *	2007-09-18	2009-08-06	The Jackson Laboratory	Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2009111315A2 (en) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Methods for reducing granulomatous inflammation
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) *	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
MX2011005691A (es)	2008-11-28	2011-07-20	Univ Emory	Metodos para el tratamiento de infecciones y tumores.
EP3255060A1 (de) *	2008-12-09	2017-12-13	F. Hoffmann-La Roche AG	Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zell-funktion
US20130101590A1 (en)	2010-04-09	2013-04-25	Heather A. Arnett	Btnl9 proteins, nucleic acids, and antibodies and uses thereof
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
ES2714708T3 (es)	2013-10-01	2019-05-29	Mayo Found Medical Education & Res	Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
PE20170255A1 (es)	2014-01-24	2017-03-22	Dana Farber Cancer Inst Inc	Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu)	2014-01-31	2019-12-30	Novartis Ag	TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko)	2014-03-14	2022-09-15	노파르티스 아게	Lag-3에 대한 항체 분자 및 그의 용도
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2016014148A1 (en)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Targeting dna-pkcs and b7-h1 to treat cancer
KR20170060042A (ko)	2014-09-13	2017-05-31	노파르티스 아게	Alk 억제제의 조합 요법
EP4245376A3 (de)	2014-10-14	2023-12-13	Novartis AG	Antikörpermoleküle gegen pd-l1 und verwendungen davon
US10786547B2 (en)	2015-07-16	2020-09-29	Biokine Therapeutics Ltd.	Compositions, articles of manufacture and methods for treating cancer
HRP20211058T8 (hr)	2015-07-29	2021-11-26	Novartis Ag	Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
WO2017165412A2 (en)	2016-03-21	2017-09-28	Dana-Farber Cancer Institute, Inc.	T-cell exhaustion state-specific gene expression regulators and uses thereof
ES3000510T3 (en)	2017-06-09	2025-02-28	Providence Health & Services Oregon	Tumor-infiltrating t-cells for use in the treatment of cancer
EP3873540A4 (de)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	Verfahren und materialien zur behandlung von krebs
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US20240277842A1 (en)	2021-06-07	2024-08-22	Providence Health & Services - Oregon	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5328470A (en) *	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6468546B1 (en)	1998-12-17	2002-10-22	Corixa Corporation	Compositions and methods for therapy and diagnosis of ovarian cancer
WO2000055375A1 (en) *	1999-03-17	2000-09-21	Alphagene, Inc.	Secreted proteins and polynucleotides encoding them
EA005140B1 (ru) *	1999-04-02	2004-12-30	Корикса Корпорейшн	Соединения и способы для лечения и диагностики рака легкого
EP1074617A3 (de) *	1999-07-29	2004-04-21	Research Association for Biotechnology	Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
JP2002171977A (ja) *	1999-07-29	2002-06-18	Herikkusu Kenkyusho:Kk	新規なヒトｓｈ２蛋白質
DE60033179T2 (de)	1999-11-12	2007-11-15	Bridgestone Corp.	Modifizierte polymere hergestellt mit katalysatoren auf basis von lanthaniden
EP1244683A4 (de) *	1999-11-12	2005-01-12	Human Genome Sciences Inc	21 menschliche sekretierte proteine
US6965018B2 (en) *	2000-06-06	2005-11-15	Bristol-Myers Squibb Company	Antibodies directed to B7-related polypeptide, BSL-2
EP1320599A2 (de) *	2000-06-28	2003-06-25	Genetics Institute, LLC	Pd-l2 moleküle: pd-l1 liganden und ihre verwendungen
EP1301524A1 (de) *	2000-06-30	2003-04-16	Human Genome Sciences, Inc.	B7-ähnliche polynukleotide, polypeptide und antikörper
US6635750B1 (en) *	2000-07-20	2003-10-21	Millennium Pharmaceuticals, Inc.	B7-H2 nucleic acids, members of the B7 family
ATE532860T1 (de) *	2000-09-20	2011-11-15	Amgen Inc	B7-ähnliche moleküle und deren anwendungen

2001
- 2001-09-19 AT AT01971167T patent/ATE532860T1/de active
- 2001-09-19 WO PCT/US2001/029183 patent/WO2002024891A2/en not_active Ceased
- 2001-09-19 EP EP01971167A patent/EP1328624B1/de not_active Expired - Lifetime
- 2001-09-19 JP JP2002529486A patent/JP4584536B2/ja not_active Expired - Fee Related
- 2001-09-19 US US09/955,866 patent/US20020107363A1/en not_active Abandoned
- 2001-09-19 CA CA002422215A patent/CA2422215A1/en not_active Abandoned
- 2001-09-19 MX MXPA03002413A patent/MXPA03002413A/es active IP Right Grant
- 2001-09-19 ES ES01971167T patent/ES2372522T3/es not_active Expired - Lifetime
- 2001-09-19 AU AU2001291087A patent/AU2001291087A1/en not_active Abandoned
2004
- 2004-11-29 US US10/998,526 patent/US7414122B2/en not_active Expired - Fee Related
2008
- 2008-04-22 JP JP2008111908A patent/JP4792057B2/ja not_active Expired - Fee Related
- 2008-06-27 US US12/163,258 patent/US20090004237A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7414122B2 (en)	2008-08-19
EP1328624B1 (de)	2011-11-09
US20090004237A1 (en)	2009-01-01
JP2008263984A (ja)	2008-11-06
WO2002024891A3 (en)	2003-04-17
AU2001291087A1 (en)	2002-04-02
WO2002024891A9 (en)	2003-11-06
JP4792057B2 (ja)	2011-10-12
ES2372522T3 (es)	2012-01-23
JP2004523215A (ja)	2004-08-05
JP4584536B2 (ja)	2010-11-24
WO2002024891A2 (en)	2002-03-28
EP1328624A2 (de)	2003-07-23
MXPA03002413A (es)	2003-06-19
CA2422215A1 (en)	2002-03-28
US20020107363A1 (en)	2002-08-08
US20050228170A1 (en)	2005-10-13

Publication	Publication Date	Title
ATE532860T1 (de)	2011-11-15	B7-ähnliche moleküle und deren anwendungen
WO2002002624A3 (en)	2002-07-04	B7-like molecules and uses thereof
DE60138715D1 (de)	2009-06-25	Tnf-rezeptor-ähnliche moleküle und deren anwendungen
MXPA02012743A (es)	2003-04-25	Moleculas tipo il-17 y usos de las mismas.
DK2077279T3 (da)	2012-12-03	Tymiske stromale lymfopoietinreceptormolekyler og anvendelser heraf
WO2001070977A3 (en)	2002-03-28	Fibroblast growth factor receptor-like molecules and uses thereof
WO2001092308A3 (en)	2002-04-11	Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2003060071A3 (en)	2004-02-26	Albumin fusion proteins
WO2001079442A3 (en)	2002-06-06	Albumin fusion proteins
WO2001061007A3 (en)	2002-03-14	Fibroblast growth factor-23 molecules and uses thereof
WO2001068854A3 (en)	2002-03-21	Fibroblast growth factor-like molecules and uses thereof
WO2001068859A3 (en)	2002-03-21	Il-17 receptor like molecules and uses thereof
WO2001068705A3 (en)	2002-07-18	Il-17 receptor like molecules and uses thereof
ATE385517T1 (de)	2008-02-15	Interferon ähnliche moleküle, und deren verwendungen
WO2003024991A3 (en)	2003-10-02	Tall-1 receptor molecules and uses thereof
WO2003087338A3 (en)	2006-01-05	Her-2 receptor tyrosine kinase molecules and uses thereof
WO2002000723A3 (en)	2002-05-30	Thymic stromal lymphopoietin receptor molecules and uses thereof
MXPA03000979A (es)	2004-08-12	Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
MXPA03010728A (es)	2004-03-02	Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
DK1196442T3 (da)	2006-05-08	VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
PL374550A1 (en)	2005-10-31	Il-17 like molecules and uses thereof
WO2002083736A3 (en)	2003-11-20	G-protein coupled receptor molecules and uses thereof
WO2001059120A3 (en)	2002-02-14	Il-17 like molecules and uses thereof
WO2001074903A3 (en)	2002-08-22	Cd20/ige-receptor like molecules and uses thereof
WO2002044379A3 (en)	2003-03-13	Transforming growth factor-beta-related molecules and uses thereof